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     BSTRACT
Meningoencephalitis of unknown etiology (MUE) is a frequently diagnosed and often fatal 
disease in veterinary neurology. The aim of this retrospective study was to assess the efficacy of 
three different sole prednisolone treatment schedules in dogs diagnosed with MUE. The dogs 
were diagnosed clinically with MUE based on previously described inclusion criteria, and treated 
with a three-, eight- or eighteen-week-tapering prednisolone schedule. Thirty eight dogs were in-
cluded in the study. Seventeen, fifteen and six dogs received the three-, eight- and eighteen-week 
tapering schedule, respectively. Overall, 37% of the dogs died or were euthanized because of 
MUE, and a significant difference in survival time was seen between the three treatment sched-
ules. Surprisingly, the highest number of dogs that died because of MUE was seen in the eight-
week treatment schedule (56%), followed by the three-week (26%) and eighteen-week (0%) 
treatment schedule. Based on the results of this study, no definitive conclusions can be drawn 
regarding the ideal prednisolone dosing protocol for dogs diagnosed with MUE. However, a more 
aggressive and immunosuppressive treatment protocol might lead to a better outcome. 
SAMENVATTING
Meningo-encefalitis van onbekende oorsprong is een vaak gediagnosticeerde neurologische aan-
doening die meestal fataal afloopt. Het doel van deze retrospectieve studie was het evalueren van drie 
behandelingsschema’s enkel bestaande uit prednisolone, gedoseerd in een afbouwend schema van drie, 
acht of achttien weken. De diagnose werd gesteld aan de hand van in de literatuur beschreven klinische 
criteria. Zevenendertig honden werden in de studie opgenomen, waarvan er zeventien, vijftien en zes 
respectievelijk het gedurende drie-, acht- en achttien-weken afbouwend schema toegediend kregen. Er 
werd een significant verschil waargenomen in overlevingstijd tussen de drie schema’s. Zevenendertig 
% van de honden in de studie stierf of werd geëuthanaseerd wegens de aandoening. Verrassend genoeg 
werd de hoogste mortaliteit vastgesteld in de groep die behandeld werd met het acht weken afbou-
wend schema (56%), gevolgd door het drie weken (26%) en het achttien weken afbouwend schema 
(0%). Gebaseerd op deze resultaten kunnen er geen definitieve conclusies getrokken worden voor wat 
betreft het ideale cortisonebehandelingsschema voor honden met meningo-encefalitis van onbekende 
oorsprong, maar een meer agressief en immunosuppressief schema zou kunnen leiden tot een lagere 
mortaliteit. 
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INTRODUCTION
Meningoencephalitis of unknown etiology (MUE) 
is a group of non-infectious central nervous system 
diseases with a likely multifactorial pathogenesis 
(Coates et al., 2014). Making a definitive diagnosis 
requires histopathological examination of central 
nervous tissue, but a presumptive antemortem clini-
cal diagnosis can be achieved based on a combina-
tion of neurological examination results, magnetic 
resonance imaging (MRI) findings and cerebrospinal 
fluid (CSF) abnormalities (Coates et al., 2014). The 
exact etiology and pathophysiology of MUE are cur-
rently unknown, but immunosuppressive drugs are 
considered to be the cornerstone of the medical treat-
ment of the disease. Several treatment protocols with 
different associated long-term survival times have 
been reported, whereby treatment with glucocortico-
steroids only is generally associated with shorter sur-
vival times (Munana and Luttgen, 1998; Jung et al., 
2007; Granger et al., 2010; Flegel et al., 2011) than 
combination therapy with other immunosuppressive 
therapies, including cytosine arabinoside, cyclospo-
rine, leflunomide, lomustine, azathioprine, myco-
phenolate mofetil or radiation therapy (Munana and 
Luttgen, 1998; Jung et al., 2007; Coates et al., 2007; 
Granger et al., 2010; Flegel et al., 2011; Beckmann et 
al., 2015; Barnoon et al., 2016). However, in a clini-
cal setting, adding more expensive immunosuppres-
sive therapies to the glucocorticoid protocol might be 
financially impossible. In a recently published pro-
spective trial in dogs with MUE, an overall median 
survival time of 602 days has been reported for dogs 
receiving immunosuppressive doses of glucocortico-
steroids starting at a dose of 1mg/kg twice daily, sup-
porting the use of monotherapy with glucocorticoste-
roids in the treatment of MUE (Mercier and Barnes 
Heller, 2015). Therefore, the aims of this study were 
to retrospectively evaluate the efficacy of three dif-
ferent prednisolone treatment protocols that were 
historically used (three-, eight- and eighteen-week- 
tapering schedule) in dogs diagnosed with MUE. In 
the study, it was assumed that a longer survival time 
would be achieved with a longer and more immuno-
suppressive treatment protocol. 
MATERIALS AND METHODS 
The electronic medical database of Ghent Univer-
sity, Small Animal Department was searched between 
March 2006 and September 2014. Owner contact was 
performed in October 2014. Adapted inclusion crite- 
ria were used (Granger et al., 2010), considering 
dogs suitable for inclusion if the following data were 
available: (1) signalment, (2) localization by neuro-
logical examination, (3) inflammatory CSF analysis, 
(4) intracranial MR and/or CT imaging results, (5) 
negative infectious disease testing, and (6) long-term 
follow-up through research of medical records or 
through telephone contact with the owner or referring 
veterinarian. Neurological status was recorded at the 
time of admission and further on a daily basis. The 
results were recorded daily in a computer program, if 
the dog was hospitalized. The outcome was defined as 
successful if dogs were not showing the previously re-
ported neurological signs or if improvement was seen 
according to the owner or referring veterinarian. An 
unsuccessful outcome was defined as death or eutha-
nasia because of disease progression or if no change 
in neurological signs was seen. Relapse was defined 
as a sudden deterioration of the neurological status 
after an initial improvement after diagnosis and initi-
ation of treatment. All dogs were only receiving glu-
cocorticosteroids as immunomodulating therapy, and 
a tapering prednisolone treatment schedule consisting 
of three, eight or eighteen weeks was used (Table 1). 
The dogs treated with the three-, eight-, eighteen-
week schedule were diagnosed between March 2006 
and March 2010,  January 2009 and August 2012, and 
January 2010 and September 2014, respectively. The 
eighteen-week treatment schedule was started with an 
immunosuppressive dose of prednisolone, being 3 mg/
kg/day, whereas the eight-week schedule was started 
at an immunosuppressive dose of 2 mg/kg/day. The 
three-week tapering schedule was started with an anti- 
inflammatory dose of 1 mg/kg/day. It was recorded 
whether dogs survived their initial treatment protocol 
and whether a relapse in neurological signs (sudden 
deterioration after initial improvement) was seen du-
ring treatment together with the associated changes 
made to the prednisolone schedule. Survival time (ST) 
Table 1. Tapering dosing schedules for oral prednisolone treatment.
 Three weeks Eight weeks Eighteen weeks
 1 week 1 mg/kg q24h 2 weeks 1 mg/kg q12h 3 weeks 1.5 mg/kg q12h
 1 week 0.5 mg/kg q24h 2 weeks 0.5 mg/kg q12h 6 weeks 1 mg/kg q12h
 1 week 0.25 mg/kg q24h 2 weeks 0.5 mg/kg q24h 3 weeks 0.5 mg/kg q12h
  2 weeks 0.25 mg/kg q24h 3 weeks 0.5 mg/kg q24h
   3 weeks 0.25 mg/kg q24h
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was defined as time from diagnosis to death or eutha-
nasia. A semiparametric cox model (hazard analysis) 
was fitted to the data to detect differences in survival 
time between the three treatment groups. All statistic 
tests were performed using S-Plus. For all analyses, a 
value of P < 0.05 was considered significant. 
 
RESULTS
Thirty-eight dogs met the inclusion criteria. 
Breeds represented included Maltese terrier (n=10), 
Yorkshire terrier (n=3), Golden retriever (n=3), Chi-
huahua (n=3), French bulldog (n=3), Pug  (n=2), La-
brador retriever (n=2), West Highland white terrier 
(n=2), Shih tzu (n=2), Boston terrier (n=2), American 
Table 2. Overview of the most important diagnostic findings in the included cases. 
Case Breed TNCC CT MRI Description Predni- Survival
num-  (WBC/μl)   imaging findings solone Time
  ber      schedule (days)
      (weeks) 
1 American Staffordshire terrier 165 Yes No No lesion visible 3 2190
2 American Staffordshire terrier 52.25 No Yes No lesion visible 3 1167
3 Boston terrier 24 No Yes Disseminated 8 1460
4 Boston terrier 15 No Yes Disseminated 8 30
5 Chihuahua 30 No Yes Focal forebrain 8 8
6 Chihuahua 9 No Yes Disseminated 18 730
7 Chihuahua 16.5 No Yes Focal cerebellum 18 70
8 German shepherd 300 No Yes Disseminated 8 10
9 Miniature schnauzer 30.25 No Yes Focal forebrain / thalamus 8 778
10 French bulldog 22 Yes No Disseminated 3 61
11 French bulldog 66 No Yes Focal brainstem 8 1275
12 French bulldog 25 No Yes Multifocal brainstem and forebrain 18 365
13 Golden retriever 118 Yes No No lesion visible 3 370
14 Golden retriever 20 No Yes Focal brainstem 3 1095
15 Golden retriever 42.6 No Yes Disseminated 18 120
16 Labrador retriever 209 No Yes Disseminated 3 1095
17 Labrador retriever 1189 No Yes Disseminated 8 150
18 Maltese terrier 74 Yes No No lesion visible 3 2190
19 Maltese terrier 66 Yes No Disseminated 3 2310
20 Maltese terrier 12.4 Yes No Disseminated 3 2035
21 Maltese terrier 800 Yes No Disseminated 3 2
22 Maltese terrier 21 No Yes Disseminated 8 13
23 Maltese terrier 64 No Yes Disseminated 8 84
24 Maltese terrier 96.25 No Yes Disseminated 8 180
25 Maltese terrier 120 No Yes Disseminated 8 1275
26 Maltese terrier 15 No Yes No lesion visible 18 730
27 Maltese terrier 50 No Yes Multifocal brainstem and forebrain 18 365
28 Pug 217 Yes No Disseminated 3 185
29 Pug 52.25 Yes No Disseminated 3 1095
30 Shih tzu 82.5 Yes Yes Disseminated 3 1921
31 Shih tzu 55 No Yes No lesion visible 8 72
32 Tervueren shepherd 27 No Yes Disseminated 8 210
33 Weimaraner 110 No Yes Disseminated 8 72
34 West Highland white terrier 33 Yes No No lesion visible 3 730
35 West Highland white terrier 500 No Yes Disseminated 8 545
36 Yorkshire terrier 33 Yes No Disseminated 3 2490
37 Yorkshire terrier 143 Yes No Disseminated 3 2490
38 Yorkshire terrier 500 Yes No Disseminated 3 6205
TNCC = total nucleated cell count; WBC = white blood cells; CT = computed tomography; MRI = magnetic resonance imaging.
Staffordshire terrier (n=2) and four other individual 
breeds. The most commonly presented neurologic 
signs were abnormal behavior (n=19), altered menta-
tion (n=18) and central vestibular signs (n=19). Brain 
imaging (CT and/or MRI) was available in all cases. 
Thirteen dogs (34%) only underwent CT imaging, 24 
dogs (63%) only underwent MR imaging and one dog 
(3%) underwent both CT and MR imaging. No lesion 
was visible in seven dogs (18%), based on CT (n=4) 
or MR (n=3) imaging. As required by the inclusion 
criteria, total nucleated cell count of the CSF was 
above reference limits (> 5WBC/µl after cisternal col-
lection) in all cases with counts ranging from 9-1189 
WBC/µl (median: 55 WBC/µl). An overview of the 
most important diagnostic findings can be consulted 
in Table 2.
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Seventeen (45%), 15 (39%), and 6 (16%) dogs 
received the three-, eight-, and eighteen-weeks pred-
nisolone treatment schedule, respectively. In eight 
dogs (21%), this therapy was combined with pheno-
barbital for treatment of seizures. There was a signi-
ficant difference in ST between the three treatment 
groups (P=0.028) (Figure 1). Overall, 24 dogs (63%) 
had a successful outcome, 22 of those dogs were 
alive at the time of data capture. The remaining two 
dogs were euthanized because of other reasons 730 
and 1167 days after their diagnosis, respectively, and 
both dogs were not receiving any immunomodulating 
medication at the time of euthanasia. Fourteen dogs 
(37%) had an unsuccessful outcome, and died or were 
euthanized because of MUE. The median survival 
time (MST) could not be calculated for the group of 
dogs receiving the three-week and eighteen-week ta-
pering prednisolone schedule, as more than 50% of 
those dogs were alive at the time of data capture. The 
MST for the dogs treated with the eight-week tape-
ring schedule, was 180 days. Five dogs died or were 
euthanized (one in the three-week group en four in the 
eight-week group) during their treatment schedule. 
No changes were made to their schedules. Ten dogs 
(26%) showed a relapse in neurological signs. Four of 
those dogs did so after terminating their three-week 
tapering schedule, three dogs after terminating their 
eight-week treatment schedule, two dogs during their 
eight-week schedule (after three and six weeks), and 
one dog after terminating the eighteen-week schedule. 
If the relapse was seen after termination of the treat-
ment schedule, the same schedule was initiated again 
(n=7), and the dose was increased again to the starting 
dose if a relapse was seen before termination of the 
tapering schedule (n=3). There was no significant dif-
ference in relapse rates between the three treatment 
schedules (P=0.886). An overview of the results can 
be found in Table 3.
 
Table 3. Summary of survival, relapse and MST in dogs within the treatment groups. 
         
  Three weeks Eight weeks Eighteen weeks
Number of dogs 17 15 6
 Dead 5 (2NR) 9 0
 Alive 10 6 6
Deceased cases   
         During protocol 1 4 0
 After protocol 4 5 0
Relapsed cases 4 5 1
 During protocol 0 2 1
 After protocol 4 3 0
Median survival time - 180 days -
NR = not related (dog died for a reason unrelated to MUE)
Figure 1. Kaplan-meier survival curve comparing survival times in the three treatment groups. Dogs that were still 
alive at the time of data capture or died because of unrelated causes, were censored for survival analysis. 
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DISCUSSION
Thirty-eight dogs diagnosed with MUE received 
oral prednisolone therapy in three different tapering 
schedules. Overall, 37% of dogs were euthanized 
because of MUE. The survival curves for the three 
treatment schedules were significantly different. Sur-
prisingly, the highest mortality rate was seen in the 
eight-week (immunosuppressive) treatment group 
(56%), followed by the three-week (anti-inflamma-
tory) (28%) and the eighteen-week (immunosuppres-
sive) treatment (0%) schedule. Possible explanations 
might be that (1) all dogs at the institution historically 
received the three-week treatment protocol when a 
suspicion of non-infectious encephalitis was made. 
However, as a possibly immune-mediated origin has 
recently been reported in the literature, dogs diag-
nosed with MUE admitted with severe neurological 
signs may have received a longer, more immunosup-
pressive (eight-week) treatment schedule and (2) the 
eighteen-week tapering schedule was only introdu-
ced in the last four years of inclusion, so the recently 
included cases in the present study might still have 
deceased in the following weeks to months, probably 
having falsely (positively) influenced the results. 
In the literature, the MST in dogs diagnosed with 
MUA and receiving sole prednisolone therapy ranges 
from 28 - 357 days (Granger et al., 2010), 91 - 329 
days (Flegel et al., 2011) and 602 days (Mercier and 
Barnes Heller, 2015). As more than 50% of the dogs 
were alive or censored for outcome calculations at the 
time of data capture, no overall MST could be calcu-
lated in the presented study. However, the MST was 
180 days in the eight-week treatment group, which 
appears to be the group with the highest percentage 
of deceased and relapsed dogs. Further prospective 
studies should be performed, including more dogs re-
ceiving the more immunosuppressive treatment sche-
dules, although comparing immunosuppressive and 
anti-inflammatory treatment protocols for a presumed 
immune-mediated disease can cause ethical dilemma.
Pitfalls in the current study are the lack of histopa-
thological confirmation of all cases, the low number 
of cases and the relatively high percentage of dogs 
that was diagnosed using CT imaging (34%). How-
ever, 18% of the dogs had no visible lesion on CT or 
MR imaging, which is comparable to the 7% for MRI 
and 14% for CT described previously (Granger et al., 
2010). Prednisolone therapy is associated with com-
mon side effects. In order to overcome these effects, 
other immunosuppressive drugs can be added to the 
protocol. Looking at the side effects of the predniso-
lone treatment was beyond the scope of this article, as 
not all of them were systematically recorded; more-
over, these effects are difficult to trace back through 
telephone contact with the owner or referring veteri-
narian. 
To conclude, the overall prognosis for dogs diag-
nosed with MUE and treated with sole prednisolone 
therapy is guarded. Almost 40% of dogs will succumb 
due to the disease. A long and immunosuppressive 
treatment schedule is advised, although side effects 
might be significant. 
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